Roche Stops Trial of HDL-Raising Drug
Even though there were no safety signals associated with dalcetrapib, the independent Data and Safety Monitoring Board recommended stopping the phase III dal-OUTCOMES trial, according to drugmaker Roche.
The board said that the second interim analysis of the trial showed the results lacked a "clinically meaningful efficacy," according to a company statement.
Dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, had two positive safety trials./.../
No comments:
Post a Comment